dr. wolf on the design of geometry mono-1 trial in metex14-mutated nsclc
Published 4 years ago • 164 plays • Length 1:44Download video MP4
Download video MP3
Similar videos
-
8:04
fda priority review of capmatinib for metex14-mutated nsclc
-
1:53
phase ii results of the geometry mono-1 study in nsclc
-
3:40
metex14 sas (met exon 14 skipping alterations) in non-small cell lung cancer
-
2:49
the challenges of treating metex14 nsclc
-
1:02
investigating met exon 14 mutations in patients with nsclc
-
1:13
dr. reckamp on pivotal data in metex14-altered nsclc
-
3:05
tepotinib in metex14 skipping alteration nsclc
-
2:24
dr. reckamp on met-targeting strategies in nsclc
-
0:46
fda approves capmatinib for advanced lung cancer
-
6:13
vision: tepotinib in met exon 14 skipping nsclc
-
1:11
detecting the met exon 14 skipping mutations in nsclc
-
4:14
crizotinib in patients with advanced met exon 14-altered nsclc
-
1:18
amivantamab for nsclc with met exon 14 skipping mutations
-
3:55
dr vibhu sharma | tepotinib in asian patients with advanced nsclc with met exon 14 skipping
-
0:58
vision trial produces positive data in nsclc with met exon 14 mutations
-
1:17
updates on met targeted therapy for exon 14 mutations in lung cancer | oncotarget